Senior Vice President, Chief Medical Officer, and Head of Research and Drug Development · IRONWOOD PHARMACEUTICALS INC (IRWD)

Michael Shetzline

A named executive officer of IRONWOOD PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,738,962

Salary $557,572Stock awards $1,982,262

FY2023: $2,595,374

4th of 5 named executive officers at Ironwood Pharmaceuticals by FY2024 total.

5 named officers on file for IRONWOOD PHARMACEUTICALS, FY2024

Michael Shetzline’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 15 equity grants, each cited to its filing
  • IRWD’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how IRONWOOD PHARMACEUTICALS’s whole pay program stands against its peers

  • IRONWOOD PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IRWD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Michael Shetzline’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Michael Shetzline compensation by year

IRONWOOD PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held
In US dollars, as IRONWOOD PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024
Salary$464,681$483,447$512,482$533,167$557,572
Bonus$100,000$121,000$121,000$0$0
Stock awards$1,121,001$1,727,931$2,080,982$1,734,924$1,982,262
Option awards$0$0$0$0$0
Non-equity incentive$194,588$285,405$188,735$309,733$180,904
Pension and deferred compensation$0$0$0$0$0
All other$11,040$18,090$15,525$17,550$18,225
Total$1,891,310$2,635,873$2,918,724$2,595,374$2,738,962

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IRONWOOD PHARMACEUTICALS INC DEF 14A filed April 28, 2025, accession 0001104659-25-040309, and prior-year filings. Open the filing on EDGAR.

How this page was built: the IRONWOOD PHARMACEUTICALS INC filed document, accession 0001104659-25-040309. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

$1.9M
$2.6M
$2.9M
$2.6M
$2.7M
FY20
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU162,115$718,169—
RSU81,447$360,810—
PSU34,936$154,766—
PSU34,934$154,758—
RSU13,607$120,558—
RSU13,606$120,549—

Per the Outstanding Equity Awards at Fiscal Year-End table in IRONWOOD PHARMACEUTICALS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2024 proxy (filed April 28, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-10Grant or award—136,612$0.00658,037
2026-02-24Sale—17,012$3.66521,425
2026-02-23Sale—15,570$3.81538,437

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

IRONWOOD PHARMACEUTICALS’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Thomas McCourtChief Executive Officer$6,083,631
Sravan EmanyFormer Senior Vice President, Chief Operating Officer and Chief Financial Officer$2,968,751
Andrew DavisFormer Senior Vice President, Chief Business Officer$2,882,732
Michael Shetzline · this pageSenior Vice President, Chief Medical Officer, and Head of Research and Drug Development$2,738,962
John MinardoSenior Vice President, Chief Legal Officer and Secretary$2,699,731

The full IRONWOOD PHARMACEUTICALS compensation record

free company brief

This page is one person within IRONWOOD PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IRONWOOD PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IRONWOOD PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Shetzline's compensation dossier · One-time report. No refunds.